Answer ALS: Individualized Initiative for ALS Discovery

Plain-language summary

This is an observational study that collects extensive data from patients to better understand amyotrophic lateral sclerosis (ALS). It enrolled people aged 18-100 with familial or sporadic ALS, as well as asymptomatic ALS gene carriers. It was conducted as a non-phase study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Johns Hopkins University

Start date

12/1/2015

Estimated completion

1/1/2020

Countries

United States

Related genes

Locations

• Los Angeles, United States
• Atlanta, United States
• Chicago, United States
• Baltimore, United States
• Boston, United States
• St Louis, United States
• Columbus, United States
• Dallas, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Participants with familial or sporadic ALS diagnosed as possible, laboratory-supported probable, probable or definite according to the World Federation of Neurology (WFN) El Escorial criteria, Primary Lateral Sclerosis Flail Arm ALS, Progressive Muscular Atrophy, Monomelic Amyotrophy, Motor Neuron Disease, Asymptomatic ALS Gene Carriers
* Participants who are ages 18-100, inclusive.

Exclusion Criteria:

* Participants with Spinal-Bulbar Muscular Atrophy
* Known diagnosis of HIV/AIDS, Hepatitis B, or Hepatitis C.